BR112014030813A2 - tratamento de efeitos colaterais de desordens motoras e de movimento associadas com tratamentos de doenças parkinson - Google Patents

tratamento de efeitos colaterais de desordens motoras e de movimento associadas com tratamentos de doenças parkinson

Info

Publication number
BR112014030813A2
BR112014030813A2 BR112014030813-6A BR112014030813A BR112014030813A2 BR 112014030813 A2 BR112014030813 A2 BR 112014030813A2 BR 112014030813 A BR112014030813 A BR 112014030813A BR 112014030813 A2 BR112014030813 A2 BR 112014030813A2
Authority
BR
Brazil
Prior art keywords
parkinson
side effects
motor
treatment
disease treatments
Prior art date
Application number
BR112014030813-6A
Other languages
English (en)
Inventor
Leahy Emer
Shankar Bavani
Original Assignee
Psychogenics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psychogenics, Inc. filed Critical Psychogenics, Inc.
Publication of BR112014030813A2 publication Critical patent/BR112014030813A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo patente de invenção: "tratamento de efeitos colaterais de desordens motoras e de movimento associadas com tratamentos de doenças parkinson". a presente invenção refere-se aos métodos de tratamento de efeitos colaterais de desordem motora associados com a administração de levodopa em um indivíduo com a doença de parkinson, por administração de uma dose de eltoprazina ou um sal de adição de ácido farmaceuticamente aceitável. em particular, a invenção proporciona métodos para a redução da discinesia associada com tratamentos da doença de parkinson, e doses eficazes de eltoprazina ou um sal de adição de ácido farmaceuticamente aceitável.
BR112014030813-6A 2012-06-11 2013-06-06 tratamento de efeitos colaterais de desordens motoras e de movimento associadas com tratamentos de doenças parkinson BR112014030813A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261658401P 2012-06-11 2012-06-11
US61/658,401 2012-06-11
PCT/US2013/044509 WO2013188210A2 (en) 2012-06-11 2013-06-06 Treatment of motor and movement disorder side effects associated with parkinson's disease treatments

Publications (1)

Publication Number Publication Date
BR112014030813A2 true BR112014030813A2 (pt) 2018-05-15

Family

ID=49715794

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014030813-6A BR112014030813A2 (pt) 2012-06-11 2013-06-06 tratamento de efeitos colaterais de desordens motoras e de movimento associadas com tratamentos de doenças parkinson

Country Status (16)

Country Link
US (2) US20130331399A1 (pt)
EP (1) EP2858649B1 (pt)
JP (3) JP2015523989A (pt)
KR (1) KR20150017763A (pt)
CN (1) CN105407879A (pt)
AU (1) AU2013274667B2 (pt)
BR (1) BR112014030813A2 (pt)
CA (1) CA2876203A1 (pt)
ES (1) ES2765200T3 (pt)
HK (1) HK1209341A1 (pt)
IL (1) IL236107A0 (pt)
MX (1) MX2014015266A (pt)
NZ (1) NZ702730A (pt)
RU (1) RU2014150942A (pt)
SG (1) SG11201408240TA (pt)
WO (1) WO2013188210A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009023253A2 (en) 2007-08-15 2009-02-19 Arena Pharmaceuticals Inc. IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
ES2666324T3 (es) 2008-10-28 2018-05-04 Arena Pharmaceuticals, Inc. Composiciones de un modulador del receptor de serotonina 5-HT2A útiles para el tratamiento de trastornos relacionados con el mismo
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
WO2016186968A1 (en) 2015-05-15 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating motor disorders
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
RU2018103338A (ru) * 2015-07-15 2019-08-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины для профилактики и лечения галлюцинаций, ассоциированных с нейродегенеративным заболеванием
KR101749675B1 (ko) * 2015-07-20 2017-06-26 동국대학교 산학협력단 멜라닌 응집 호르몬을 유효성분으로 포함하는 파킨슨병 치료 및 레보도파 부작용 억제용 약학 조성물
US20190054051A1 (en) * 2017-08-21 2019-02-21 The Board Of Trustees Of The Leland Stanford Junior University DOPA Formulations for Treatments of Parkinson's Disease
WO2020110128A1 (en) * 2018-11-29 2020-06-04 Prilenia Neurotherapeutics Ltd. Combination of pridopidine and an additional therapeutic agent for treating drug induced dyskinesia
US11517548B2 (en) 2018-07-19 2022-12-06 Impel Pharmaceuticals Inc. Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's Disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19938823A1 (de) * 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
US7706871B2 (en) * 2003-05-06 2010-04-27 Nellcor Puritan Bennett Llc System and method of prediction of response to neurological treatment using the electroencephalogram
EP2374459A1 (en) * 2008-05-30 2011-10-12 Psychogenics Inc. Treatment for neurological and mental disorders
US20110183995A1 (en) * 2008-06-24 2011-07-28 Neurosearch A/S Eltoprazine for suppression of l-dopa induced dyskinesias
DE102008030539B4 (de) * 2008-06-27 2016-05-12 BSH Bosch und Siemens Hausgeräte GmbH Haushaltsgerät
EP3586923B1 (en) * 2008-07-14 2021-06-16 Arizona Board Of Regents For And On Behalf Of Arizona State University Devices for modulating cellular activity using ultrasound
TW201029995A (en) * 2008-12-05 2010-08-16 Merz Pharma Gmbh & Co Kgaa Use of eltoprazine for the treatment of L-DOPA-induced dyskinesia
RU2611376C2 (ru) * 2010-10-15 2017-02-21 Контера Фарма Апс Фармацевтическая композиция для лечения, профилактики или облегчения двигательных расстройств и ее применение

Also Published As

Publication number Publication date
WO2013188210A2 (en) 2013-12-19
EP2858649A4 (en) 2016-05-25
IL236107A0 (en) 2015-01-29
RU2014150942A (ru) 2016-07-27
CA2876203A1 (en) 2013-12-19
US20130331399A1 (en) 2013-12-12
CN105407879A (zh) 2016-03-16
ES2765200T3 (es) 2020-06-08
US20180250295A1 (en) 2018-09-06
KR20150017763A (ko) 2015-02-17
JP2018083842A (ja) 2018-05-31
EP2858649B1 (en) 2019-10-23
SG11201408240TA (en) 2015-01-29
WO2013188210A3 (en) 2015-07-02
JP2020073549A (ja) 2020-05-14
NZ702730A (en) 2017-08-25
AU2013274667A1 (en) 2015-01-22
AU2013274667B2 (en) 2018-03-08
HK1209341A1 (en) 2016-04-01
JP2015523989A (ja) 2015-08-20
EP2858649A2 (en) 2015-04-15
MX2014015266A (es) 2015-06-23

Similar Documents

Publication Publication Date Title
BR112014030813A2 (pt) tratamento de efeitos colaterais de desordens motoras e de movimento associadas com tratamentos de doenças parkinson
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
BR112013031032A2 (pt) inibidores de sglt-2 para o tratamento de distúrbios metabólicos em pacientes tratados com agentes neurolépticos
BR112014010803A2 (pt) método de tratamento
BR112015018438A2 (pt) anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento
BR112015025424A2 (pt) tratamento de câncer usando terapias de combinação de coenzima q10
BR112015027297A8 (pt) administração local e concomitante de nanocarreadores sintéticos tolerogênicos para reduzir hipersensibilidade dos tipos i e iv
BR112014003414A2 (pt) método de produção de níveis fisiológicos e terapêuticos de óxido nítrico através de um sistema de entrega oral
BR112015001847A2 (pt) composições e tratamento para doenças e distúrbios nos olhos
BR112012017073A2 (pt) Método de tratamento de condições neurológicas com glicosídeos cardíacos
BR112014013924A8 (pt) métodos para tratar distúrbios cardiovasculares
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
BR112013029246A2 (pt) 4-amino-5-flúor-3-[6- (4-metilpiperazin- 1 - il) - 1h - benzimidazol - 2 - il] - 1h - quinolin-2-ona para uso no tratamento de carcinoma adenoide cístico
BR112014031806A8 (pt) método para tratamento de câncer positivo para gd2
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
BR112015022390A2 (pt) método para o tratamento de doença de parkinson
BR112015017775A2 (pt) enzima cistationina beta-sintase para o tratamento de homocistinúria
BR112015022623A2 (pt) composição e métodos baseados em anticorpos neutralizantes, administrados por via intranasal para eficácia terapêutica melhorada
BR112014003704A2 (pt) moduladores ror gama
BR112014001170A2 (pt) cateter, especialmente um cateter permanente, para tratamento de problemas funcionais e/ou doenças da bexiga e/ou próstata
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112012030764A2 (pt) métodos para tratamento de distúrbios metotrexato-resistentes com 10-propargil-10-deazaanibopterin
BR112014002674A2 (pt) 3-(bifenil-3-il)-4-hidróxi-8-metóxi-1-azaspiro[4.5]dec-3-en-2-onas substituídas
BR112014010729A2 (pt) métodos para tratamento de ataques de gota
MX2016000220A (es) Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements